MEDIGENE AG (MDG1.DE) Stock Price, Quote, News and Overview
FRA:MDG1 - Deutsche Boerse Ag - DE000A40ESG2 - Common Stock - Currency: EUR
MDG1.DE Quote, Performance and Key Statistics
FRA:MDG1 (3/25/2025, 7:00:00 PM)
1.578
-0.02 (-1.13%)
The current stock price of MDG1.DE is 1.578 EUR. In the past month the price decreased by -4.83%. In the past year, price decreased by -25.21%.
MDG1.DE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1ABBV.MI | ABBVIE INC | 20.71 | 341.81B | ||
| 4AB.DE | ABBVIE INC | 19.94 | 329.20B | ||
| AMG.DE | AMGEN INC | 15.58 | 153.24B | ||
| GIS.DE | GILEAD SCIENCES INC | 23.88 | 126.70B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 1736.67 | 120.41B | ||
| ARGX.BR | ARGENX SE | 341.12 | 33.16B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.64B | ||
| IDP.DE | BIOGEN INC | 8.55 | 19.04B | ||
| 1MRNA.MI | MODERNA INC | N/A | 12.15B | ||
| 0QF.DE | MODERNA INC | N/A | 11.52B | ||
| BIO.DE | BIOTEST AG | 23.86 | 1.61B | ||
| GLPG.AS | GALAPAGOS NV | 21.21 | 1.57B |
Related stock screener links
About MDG1.DE
Company Profile
Medigene AG is a DE-based company operating in Biotechnology industry. The company is headquartered in Planegg, Bayern and currently employs 86 full-time employees. The company went IPO on 2000-06-30. Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The firm focuses on the development of personalized T cell-based immunotherapies. The company develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors. The firm operates offices in Martinsried in Germany, as well as in Washington DC and San Diego in the United States.
Company Info
MEDIGENE AG
Lochhamer Strasse 11
Planegg BAYERN DE
Employees: 87
Company Website: https://www.medigene.de/
Investor Relations: http://www.medigene.com/investors-media/
Phone: 49892000330
MEDIGENE AG / MDG1.DE FAQ
What is the stock price of MEDIGENE AG today?
The current stock price of MDG1.DE is 1.578 EUR. The price decreased by -1.13% in the last trading session.
What is the ticker symbol for MEDIGENE AG stock?
The exchange symbol of MEDIGENE AG is MDG1 and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is MDG1.DE stock listed?
MDG1.DE stock is listed on the Deutsche Boerse Ag exchange.
What is the price forecast or stock price prediction for MEDIGENE AG stock?
8 analysts have analysed MDG1.DE and the average price target is 2.96 EUR. This implies a price increase of 87.45% is expected in the next year compared to the current price of 1.578. Check the MEDIGENE AG stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MEDIGENE AG worth?
MEDIGENE AG (MDG1.DE) has a market capitalization of 23.50M EUR. This makes MDG1.DE a Nano Cap stock.
How many employees does MEDIGENE AG have?
MEDIGENE AG (MDG1.DE) currently has 87 employees.
What are the support and resistance levels for MEDIGENE AG (MDG1.DE) stock?
MEDIGENE AG (MDG1.DE) has a support level at 1.57 and a resistance level at 1.62. Check the full technical report for a detailed analysis of MDG1.DE support and resistance levels.
Is MEDIGENE AG (MDG1.DE) expected to grow?
The Revenue of MEDIGENE AG (MDG1.DE) is expected to grow by 100% in the next year. Check the estimates tab for more information on the MDG1.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy MEDIGENE AG (MDG1.DE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MDG1.DE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MDG1.DE, evaluating the profitability, health, valuation and growth aspects
- MEDIGENE AG (MDG1.DE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MEDIGENE AG (MDG1.DE) Sales and EPS estimates to see what analysts future expectations are.
- MEDIGENE AG (MDG1.DE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MEDIGENE AG (MDG1.DE) Insider and Institutional Ownership to learn about the owners and their transactions.
- MEDIGENE AG (MDG1.DE) Stock Chart to make your own analysis
- MEDIGENE AG (MDG1.DE) Latest news and press-releases to stay up to date.
Does MEDIGENE AG (MDG1.DE) stock pay dividends?
MDG1.DE does not pay a dividend.
When does MEDIGENE AG (MDG1.DE) report earnings?
MEDIGENE AG (MDG1.DE) will report earnings on 2025-03-26, after the market close.
What is the Price/Earnings (PE) ratio of MEDIGENE AG (MDG1.DE)?
MEDIGENE AG (MDG1.DE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.25).
MDG1.DE Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to MDG1.DE. When comparing the yearly performance of all stocks, MDG1.DE is one of the better performing stocks in the market, outperforming 83.95% of all stocks.
MDG1.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MDG1.DE. The financial health of MDG1.DE is average, but there are quite some concerns on its profitability.
MDG1.DE Financial Highlights
Over the last trailing twelve months MDG1.DE reported a non-GAAP Earnings per Share(EPS) of -1.25. The EPS decreased by -94.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -56.15% | ||
| ROE | -82.28% | ||
| Debt/Equity | 0.08 |
MDG1.DE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to MDG1.DE. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 38.46% and a revenue growth 100% for MDG1.DE